The Balm of Gilead: Is the Provision of Treatment to Those Who Seroconvert in HIV Prevention Trials a Matter of Moral Obligation or Moral Negotiation?
Authors:
- 1 January 2006
- journal article
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 34 (4) , 793-808
Abstract
Must treatment be provided to subjects who acquire HIV during the course of a prevention study? An analysis of ethical foundation, regulation, and recent argumentation provides no basis for the obligation. We outline an alternative approach to the problem based on moral negotiation.Keywords
This publication has 14 references indexed in Scilit:
- Fiduciary Obligation in Clinical ResearchJournal of Law, Medicine & Ethics, 2006
- The trials of tenofovir trialsThe Lancet, 2005
- Provision of HIV treatment in HIV preventive vaccine trials: a developing country perspectiveSocial Science & Medicine, 2005
- HIV prevention research and global inequality: steps towards improved standards of careJournal of Medical Ethics, 2005
- Treating people with intercurrent infection in HIV prevention trialsAIDS, 2004
- When are research risks reasonable in relation to anticipated benefits?Nature Medicine, 2004
- Moral Standards for Research in Developing Countries from "Reasonable Availability" to "Fair Benefits"Hastings Center Report, 2004
- Provision of treatment in HIV-1 vaccine trials in developing countriesThe Lancet, 2003
- International Research EthicsBioethics, 2000
- Protecting communities in research: current guidelines and limits of extrapolationNature Genetics, 1999